The analysis technique used for these patients consisted of placing an inverted T on the preplan ultrasound and the corresponding postimplant CT axial image with the back of the T placed at the posterior aspect of the prostate. The ultrasound and CT images in this way were fused together to allow transfer of the volumes drawn initially on the preimplant ultrasound to be superimposed on the postimplantation CT scan. The authors defined “excellent” target coverage as V100 of 90% or greater and D90 of 100% or greater. Using these criteria, 48% of the implants were considered as having excellent dosimetry. In an earlier selleck inhibitor report

(12), these authors defined a cohort of implants that were defined as “too cool” with V100 lower than 80% and/or D90 lower than 90%. Using these latter criteria, the percent of implant procedures that Selleckchem GSK3 inhibitor were “cool” and considered inadequate ranged from 13% to 36%. The value of the postimplantation CT assessment is well recognized and considered the standard mode of post-implantation quality assessment. Several reports have indicated that the quality of the dose delivery to the prostate is associated with long-term biochemical tumor control. Stock et al. (2) had reported

that D90 values lower than 140 Gy were associated with a higher incidence of prostate-specific antigen failure. A large multiinstitutional study demonstrated that D90 greater than 130 Gy was associated with an 8-year prostate-specific antigen relapse-free survival of 93% compared with 76% among patients who had posttreatment

D90 values lower than 130 Gy (7). Recently, investigators from Memorial Sloan–Kettering Cancer Center have shown that D90 greater than 140 Gy based on the dosimetric assessment of a postimplantation CT scan obtained on the day of the brachytherapy procedure predicted for improved long-term biochemical tumor control (5). Notwithstanding these findings, it is important to note that a dosimetric analysis indicative of suboptimal dose coverage will not necessarily result MG-132 mouse in an inferior tumor control outcome. Especially for patients with disease confined to a particular region within the prostate where the dose distribution happens to be adequate, tumor control would be expected despite what may be considered inadequate dose coverage for the rest of the gland. We acknowledge that there are limitations of the CT postimplantation assessment, which include postprocedure edema that can at times mistakenly characterize an implant as inadequate. Nevertheless, the postimplantation CT as a QA assessment is still considered standard of care after prostate brachytherapy and provides an opportunity for the radiation oncologist to perform a critical assessment of the inadequacies of target coverage.